In the spring of 2016, the U.S. Food and Drug Administration approved the first biosimilar product in the U.S. Biosimilars are not new to the industry; they have been on the market in Europe since 2006. But, this newer practice has pharma watching closely as it could determine innovative, lower cost go-to-market therapies. The following article describes the argument, fallout and possible solutions for the introduction of biosimilars as therapeutic substitutions. To learn more, complete the form to request our resource.
We were really surprised at the amount of detail we received. We are very happy with the online session.Brand Leader